Physician profile
Mark Spitzer
NPI 1306819438
$23,910.57
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,433 · 2020: $10K · 2021: $1,558 · 2022: $2,555.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11,384.42 | 2019-2020 | |
| Gen-Probe, INC. | $6,890.63 | 2020 | |
| Scynexis, INC. | $3,955.45 | 2021-2022 | |
| Hologic INC | $1,312.50 | 2020 | |
| Agile Therapeutics, INC. | $157.62 | 2021 | |
| Therapeuticsmd, INC. | $154.71 | 2019-2020 | |
| Abbvie INC. | $41.49 | 2019 | |
| Dysis Medical, INC. | $13.75 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Spitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.